骨髓增生异常综合征患者血清β_2-微球蛋白水平的预后价值  

Prognostic significance of serum β_2 microglobulin levels in patients with myelodysplastic syndromes(MDS)

作　　者：上官辉[1] 谭淑燕[2] 汪宝贞[1] 

机构地区：[1]佛山市第二人民医院血液内科,广东佛山528000 [2]佛山市第二人民医院感染内科,广东佛山528000

出　　处：《海南医学》2010年第5期8-9,共2页Hainan Medical Journal

摘　　要：目的探讨骨髓增生异常综合征(Myelodysplastic syndrome,MDS)患者血清β2-微球蛋白(β2-MG)水平与预后的关系。方法测定58例MDS患者治疗前的空腹血清β2-MG水平,将患者分为β2-MG≥2.0mg/L和β2-MG<2.0mg/L两组,比较两组患者的外周血白细胞计数、血红蛋白值、血小板计数和患者的生存时间。结果β2-MG水平高于2.0mg/L组的患者外周血白细胞计数、血红蛋白值、血小板计数和生存期差于β2-MG水平低于2.0mg/L组的患者。结论β2-MG水平高低与MDS患者的预后有相关性。Objective To investigate the level of serum β2-mieroglobulin （ β2-MG） and its role in prognosis in myelodysplastie syndromes （MDS）. Methods Serum β2-MG levels were determined in 58 patients with MDS. Patients were divided into two groups according to the value of serum β2- MG level, hemoglobin level, leukocyte count and thrombocyte count was also recorded. Results An elevated β2- MG （ ≥2.0 mg/L） was found to be associated with decreased probability of survival （ P 〈 0.05 ） , it is lower in the level of hemoglobin level, leukocyte count and thrombocyte count. Conclusion Serum β2- MG levels may be helpful to know the prognosis in patients with MDS.

关 键 词：骨髓增生异常综合症 Β-微球蛋白 预后 

分 类 号：R551.3[医药卫生—血液循环系统疾病]